Sanofi Aims to Rebuild Trust with Regeneron; Apnimed's Upsized IPO Adds Momentum
New Sanofi CEO Belén Garijo has identified rebuilding trust and transparency in the company’s partnership with Regeneron Pharmaceuticals as a key priority. This follows recent program cuts, including high-profile immune drug candidates like amlitelimab and itepekimab. With Dupixent facing an impending patent cliff, Sanofi plans to intensify M&A activity while strengthening its alliance with Regeneron. Meanwhile in the biotech sector, Apnimed successfully raised $192 million through an upsized IPO on Thursday, reflecting strong investor demand and becoming one of 15 biopharma companies to go public this year. The trend highlights continued confidence in emerging therapeutic areas like sleep disorders.
Topics: executive leadership IPO activity M&A strategic partnership